目的 探讨海曲泊帕乙醇胺片联合重组人血小板生成素（rhTPO）治疗实体肿瘤治疗相关性血小板减少症的临床疗效以及其对患者血清促血小板生成素（TPO）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平的影响。方法 回顾性选择河南科技大学第一附属医院2021年9月—2022年6月收治的88例实体肿瘤治疗相关性血小板减少症患者作为研究对象，根据治疗方案不同分为对照组和试验组，每组44例。试验组给予海曲泊帕乙醇胺片联合rhTPO治疗，对照组单用rhTPO治疗。比较两组治疗前以及治疗第3、7、14天时血小板计数，并比较两组血小板计数恢复至≥75×10⁹·L^-1、≥100×10⁹·L^-1所需时间。治疗第 14天时根据试验对象血小板计数变化情况进行疗效评估。治疗前后检测两组患者的血清 TPO、IL-6、TNF-α水平。记录并比较两组不良反应情况。结果 试验组总有效率为 90.91%，与对照组（65.91%）相比显著升高（P＜0.05）。两组治疗前血小板计数比较差异无统计学意义（P＞0.05）。两组治疗第 3、7、14天时血小板计数均逐渐升高，且均显著高于治疗前（P＜0.05）。治疗第3、7、14天时，试验组血小板计数均显著高于同期对照组（P＜0.05）。试验组血小板计数恢复至≥75×10⁹·L^-1、≥100×10⁹·L^-1所需时间均显著短于对照组（P＜0.05）。治疗后，两组血清TPO、IL-6、TNF-α水平均较治疗前显著降低（P＜0.05）；且治疗后，试验组血清 TPO、IL-6、TNF-α 水平均显著低于对照组（P＜0.05）。试验组不良反应发生率为 15.91%，对照组为 11.36%，两组间比较差异无统计学意义（P＞0.05）。结论 海曲泊帕乙醇胺片联合 rhTPO治疗 SCTRT能有效升高患者体内血小板水平，下调血清TPO、IL-6、TNF-α水平，总体疗效确切，且不明显增加不良反应的发生风险。

Objective To investigate the clinical efficacy of Herombopag Olamine Tablets combined with recombinant human thrombopoietin (rhTPO) in treatment of solid tumor treatment-associated thrombocytopenia (SCTRT) and its effect on serum levels of thrombopoietin (TPO), interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α). Methods A total of 88 SCTRT patients admitted to The First Affiliated Hospital of Henan University of Science and Technology from September 2021 to June 2022 were selected as the research objects and divided into two groups according to the random number table method, with 44 cases in each group. Patients in the experimental group were treated with Herombopag Olamine Tablets combined with rhTPO, while patients in the control group were treated with rhTPO alone. The platelet counts were compared between the two groups before treatment and on the 3rd, 7th, and 14th day of treatment, and the time required for the platelet counts to rise to ≥ 75 × 10⁹·L^-1 and ≥100 × 10⁹·L^-1 were compared between the two groups. The efficacy was evaluated according to the change of platelet count on the 14th day of treatment. The serum levels of TPO, IL-6 and TNF-α were detected before and after treatment. The adverse reactions of the two groups were recorded and compared. Results The total effective rate of the experimental group was 90.91%, which was significantly higher than that of the control group (65.91%, P＜0.05). There was no significant difference in platelet count between the two groups before treatment (P＞0.05). The platelet counts of the two groups were gradually increased on the 3rd, 7th and 14th day of treatment, and were significantly higher than those before treatment (P＜0.05). On the 3rd, 7th and 14th day of treatment, the platelet count in the experimental group was significantly higher than that in the control group (P＜0.05). The time required for platelet count to rise to ≥ 75 × 10⁹·L^-1 and ≥ 100 × 10⁹·L^-1 in the experimental group was significantly shorter than that in the control group (P＜0.05). After treatment, the serum levels of TPO, IL-6 and TNF- α in the two groups were significantly decreased compared with those before treatment (P＜0.05). After treatment, the serum levels of TPO, IL-6 and TNF-α in the experimental group were significantly lower than those in the control group (P＜0.05). The incidence of adverse reactions was 15.91% in the experimental group and 11.36% in the control group, and there was no significant difference between the two groups (P＞0.05). Conclusion Herombopag Olamine Tablets combined with rhTPO in treatment of SCTRT can effectively increase the level of platelet in patients with SCTRT, and down-regulate the levels of serum TPO, IL-6, TNF-α. The overall efficacy is exact, and does not increase the risk of adverse reactions.

R973